InMed Pharmaceuticals Inc.
We are a pharmaceutical company developing a pipeline of proprietary small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. CB1 and CB2 receptors are each part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions.
$1.32
-$0.01 (-0.75%)
EOD Oct 16, 2026
Negative free cash flow of -$9M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$13M
▼ -53.9% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$9M
▼ -6.7% YoY
Op. Cash Flow (TTM)
-$9M
▼ -6.7% YoY
Net Debt
-$2M
Net Cash Position
Cash & Equiv.
$2M
3Y CAGR: +65.5%
Continue Research
SourceComputed from the 10-Q filed 2 Sept 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 10 Sept 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is InMed Pharmaceuticals (INM) overvalued?
InMed Pharmaceuticals (INM)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, InMed Pharmaceuticals scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is InMed Pharmaceuticals a high-quality business?+
InMed Pharmaceuticals scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is InMed Pharmaceuticals a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh INM's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.